# US 2024/0200038 A1 · Method for separating and purifying influenza virus-like particles (vlps) using aqueous two-phase system (atps)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200038 A1
- Document ID: US20240200038A1
- Status: Published application
- Kind: A1
- Application number: 18/483,293
- Filed: 2023-10-09
- Published: 2024-06-20
- Earliest claimed: 2022-12-15
- Assignees: ZJ Huadi Pharma Group Pharma Development Co., Ltd.
- Applicants: ZJ Huadi Pharma Group Pharma Development Co., Ltd.
- Inventors: Yang WANG; Baobin YU
- Web page: https://patentgrep.com/patent/US20240200038A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2760/16123: Virus like particles [VLP]
- C12N 2760/16151: Methods of production or purification of viral material
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure relates to the technical field of separation and purification of virus-like particles (VLPs), in particular to a method for separating and purifying influenza VLPs using an aqueous two-phase system (ATPS). In the method for separating and purifying influenza VLPs by an ATPS of the present disclosure, a phosphate buffer as a phase-forming salt is mixed with PEG400 to form an aqueous two phase-based extraction system to extract the influenza VLPs. Compared with the prior art, the method for separating and purifying the influenza VLPs has a simple process, which only requires allowing to stand and centrifugation to form an aqueous two phase; and liquids in upper and lower phases can be recycled and reused. The method shows a low cost and environmental friendliness. The extracted influenza VLPs have desirable purity, and a structure and an activity of the influenza VLPs are maintained.

## Claims

### Claim 1

An aqueous two phase-based phase-forming agent composition, comprising a phosphate buffer and a PEG400 solution, wherein the phosphate buffer comprises water, KH2PO4, and K2HPO4.

### Claim 2 (depends on 1)

The aqueous two phase-based phase-forming agent composition according to claim 1, wherein in the phosphate buffer, the KH2PO4 has a mass fraction of 3.92 wt % to 6.72 wt %, and the K2HPO4 has a mass fraction of 10.08 wt % to 17.28 wt %; and the PEG400 solution comprises water and PEG400 with a mass fraction of 14 wt % to 24 wt %.

### Claim 3 (depends on 2)

The aqueous two phase-based phase-forming agent composition according to claim 2, wherein in the phosphate buffer, the KH2PO4 has a mass fraction of 5.04 wt %, and the K2HPO4 has a mass fraction of 12.96 wt %; and in the PEG400 solution, the PEG400 has a mass fraction of 20 wt %.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

A method for separating and purifying virus-like particles (VLPs) in an aqueous two phase, comprising: separating and purifying a crude extract of the VLPs using the aqueous two phase-based phase-forming agent composition according to 1.

### Claim 7 (depends on 6)

The method according to claim 6, wherein a process of separating and purifying the crude extract comprises:
mixing the crude extract of the VLPs with the aqueous two phase-based phase-forming agent composition, allowing to stand to form a liquid-liquid two-phase system, conducting primary centrifugation to form a liquid-solid-liquid three-phase system, and recovering an intermediate solid phase; and
dissolving the solid phase in a PBS solution, and conducting secondary centrifugation to obtain a solution of the VLPs.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the crude extract is separated and purified at 18° C. to 35° C.; the primary centrifugation is conducted at 3,000 rpm for 5 min, and the secondary centrifugation is conducted at 6,000 rpm for 15 min.

### Claim 9 (depends on 6)

The method according to claim 6, wherein a preparation process of the crude extract comprises:
constructing an Agrobacterium strain containing a viral recombinant plasmid to infect a plant tissue; crushing and extracting an obtained infected plant tissue with a Tris-Borate-Ethylenediaminetetraacetic acid (EDTA) (TBE) extractant; and subjecting an obtained extracted product to centrifugation to obtain the crude extract of the VLPs.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the TBE extractant comprises water, 10 mmol/L of EDTA, 0.45 mol/L of H3BO3, and 0.45 mol/L of a Tris salt.

### Claim 11 (depends on 6)

The method according to claim 6, wherein in the phosphate buffer, the KH2PO4 has a mass fraction of 3.92 wt % to 6.72 wt %, and the K2HPO4 has a mass fraction of 10.08 wt % to 17.28 wt %; and the PEG400 solution comprises water and PEG400 with a mass fraction of 14 wt % to 24 wt %.

### Claim 12 (depends on 11)

The method according to claim 11, wherein in the phosphate buffer, the KH2PO4 has a mass fraction of 5.04 wt %, and the K2HPO4 has a mass fraction of 12.96 wt %; and in the PEG400 solution, the PEG400 has a mass fraction of 20 wt %.

### Claim 13 (depends on 11)

The method according to claim 11, wherein a process of separating and purifying the crude extract comprises:
mixing the crude extract of the VLPs with the aqueous two phase-based phase-forming agent composition, allowing to stand to form a liquid-liquid two-phase system, conducting primary centrifugation to form a liquid-solid-liquid three-phase system, and recovering an intermediate solid phase; and dissolving the solid phase in a PBS solution, and conducting secondary centrifugation to obtain a solution of the VLPs.

### Claim 14 (depends on 12)

The method according to claim 12, wherein a process of separating and purifying the crude extract comprises:
mixing the crude extract of the VLPs with the aqueous two phase-based phase-forming agent composition, allowing to stand to form a liquid-liquid two-phase system, conducting primary centrifugation to form a liquid-solid-liquid three-phase system, and recovering an intermediate solid phase; and dissolving the solid phase in a PBS solution, and conducting secondary centrifugation to obtain a solution of the VLPs.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the crude extract is separated and purified at 18° C. to 35° C.; the primary centrifugation is conducted at 3,000 rpm for 5 min, and the secondary centrifugation is conducted at 6,000 rpm for 15 min.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the crude extract is separated and purified at 18° C. to 35° C.; the primary centrifugation is conducted at 3,000 rpm for 5 min, and the secondary centrifugation is conducted at 6,000 rpm for 15 min.

### Claim 17 (depends on 11)

The method according to claim 11, wherein a preparation process of the crude extract comprises: constructing an Agrobacterium strain containing a viral recombinant plasmid to infect a plant tissue; crushing and extracting an obtained infected plant tissue with a Tris-Borate-Ethylenediaminetetraacetic acid (EDTA) (TBE) extractant; and
subjecting an obtained extracted product to centrifugation to obtain the crude extract of the VLPs.

### Claim 18 (depends on 12)

The method according to claim 12, wherein a preparation process of the crude extract comprises: constructing an Agrobacterium strain containing a viral recombinant plasmid to infect a plant tissue; crushing and extracting an obtained infected plant tissue with a Tris-Borate-Ethylenediaminetetraacetic acid (EDTA) (TBE) extractant; and
subjecting an obtained extracted product to centrifugation to obtain the crude extract of the VLPs.

### Claim 19 (depends on 7)

The method according to claim 7, wherein a preparation process of the crude extract comprises: constructing an Agrobacterium strain containing a viral recombinant plasmid to infect a plant tissue; crushing and extracting an obtained infected plant tissue with a Tris-Borate-Ethylenediaminetetraacetic acid (EDTA) (TBE) extractant; and
subjecting an obtained extracted product to centrifugation to obtain the crude extract of the VLPs.

### Claim 20 (depends on 13)

The method according to claim 13, wherein a preparation process of the crude extract comprises: constructing an Agrobacterium strain containing a viral recombinant plasmid to infect a plant tissue; crushing and extracting an obtained infected plant tissue with a Tris-Borate-Ethylenediaminetetraacetic acid (EDTA) (TBE) extractant; and
subjecting an obtained extracted product to centrifugation to obtain the crude extract of the VLPs.

### Claim 21 (depends on 14)

The method according to claim 14, wherein a preparation process of the crude extract comprises: constructing an Agrobacterium strain containing a viral recombinant plasmid to infect a plant tissue; crushing and extracting an obtained infected plant tissue with a Tris-Borate-Ethylenediaminetetraacetic acid (EDTA) (TBE) extractant; and
subjecting an obtained extracted product to centrifugation to obtain the crude extract of the VLPs.

### Claim 22 (depends on 8)

The method according to claim 8, wherein a preparation process of the crude extract comprises: constructing an Agrobacterium strain containing a viral recombinant plasmid to infect a plant tissue; crushing and extracting an obtained infected plant tissue with a Tris-Borate-Ethylenediaminetetraacetic acid (EDTA) (TBE) extractant; and
subjecting an obtained extracted product to centrifugation to obtain the crude extract of the VLPs.
